Replies to post #131171 on Biotech Values

[jq1234]

I think MDVN made a strategic blunder in partnering out the US with Astellas. If the US were unencumbered these guys could write their own ticket right now.

Where would MDVN get the money to conduct two phase 3 trials with almost 3,000 patients total in chemo treated and chemo naive CRPC patients if they hadn't partnered with Astellas?